<DOC>
	<DOCNO>NCT00260208</DOCNO>
	<brief_summary>Following transplant hepatitis C cirrhosis , infection come back 70-90 % case time cause fibrosis eventually cirrhosis new liver . The aim study see frequency liver fibrosis different cyclosporine microemulsion tacrolimus</brief_summary>
	<brief_title>Liver Fibrosis Patients Transplanted Hepatitis C Receiving Either Cyclosporine Microemulsion Tacrolimus</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>Inclusion criterion Reason transplant endstage liver disease due hepatitis C cirrhosis Patients receive first liver transplant decease live donor Patients biopsies possible Exclusion criterion Recipients liver hepatitis C virus positive ( HCV+ ) , human immunodeficiency virus positive ( HIV+ ) hepatitis B virus positive ( HBV+ ) donor Patients severe coexist disease suffer unstable medical condition coinfected HBV HIV Patients coexist alcoholic disease abstinent least 6 month Transplanted liver cancer exceed predefined size Pregnant nursing woman Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>Liver transplant , adult , hepatitis C , liver fibrosis , cyclosporine microemulsion , tacrolimus</keyword>
</DOC>